The five-year relative survival rate for stage 4 (metastatic) breast cancer is 32.6%, based on the most recent national data. That means roughly one in three women diagnosed with distant-stage breast cancer are alive five years later. About 13% survive ten years or longer. These numbers are averages across all subtypes and treatment approaches, and individual outcomes vary widely depending on the biology of the cancer, where it has spread, and how it responds to treatment.
What the Overall Numbers Look Like
Stage 4 breast cancer means the cancer has spread beyond the breast and nearby lymph nodes to distant organs, most commonly the bones, lungs, liver, or brain. Only about 6% of breast cancer cases are diagnosed at this stage. The national survival data comes from the SEER program, which tracks cancer outcomes across the United States. The 32.6% five-year survival figure reflects diagnoses from 2015 through 2021, so it captures many but not all of the newest treatments now available.
Median survival, the point at which half of patients are still alive, generally falls somewhere between two and three years across all subtypes. But that median masks enormous variation. Some women live months, others live a decade or more. The factors that matter most are the cancer’s molecular subtype, how many organs are involved, and whether the cancer responds well to its first line of treatment.
How Cancer Subtype Shapes Survival
Breast cancer is not one disease. It’s classified by whether the tumor has hormone receptors (for estrogen or progesterone) and whether it overproduces a protein called HER2. These molecular features determine which treatments work and have a major influence on how long someone lives with metastatic disease.
Hormone Receptor Positive, HER2 Negative
This is the most common subtype, making up roughly 70% of breast cancers. It tends to grow more slowly than other subtypes, and it responds to hormone-blocking therapies. Adding a class of targeted drugs that interrupt cancer cell division (CDK4/6 inhibitors) to hormone therapy has become standard first-line treatment. In clinical trials and meta-analyses, these drugs improved median survival by 4 to 10 months compared with hormone therapy alone, with a 19% to 29% reduction in the risk of death. Many women with this subtype live three to five years or longer with metastatic disease, particularly when the cancer spreads only to bone.
HER2 Positive
HER2-positive cancers were once among the most aggressive, but targeted therapies have dramatically changed that picture. A 2025 trial published in the New England Journal of Medicine showed that a newer antibody-drug conjugate combined with another targeted therapy achieved a median progression-free survival of 40.7 months, meaning the cancer didn’t worsen for nearly three and a half years. That compares to 26.9 months with the previous standard approach. HER2-positive metastatic breast cancer now often has the longest survival of any subtype, with many patients living five years or more.
Triple Negative
Triple-negative breast cancer (TNBC) lacks hormone receptors and doesn’t overproduce HER2, which means it doesn’t respond to hormone therapy or HER2-targeted drugs. It historically carries the shortest survival times. Adding immunotherapy to chemotherapy has improved outcomes for a subset of patients whose tumors test positive for a protein called PD-L1. In that group, immunotherapy added about seven months to median overall survival. For PD-L1 negative triple-negative cancers, chemotherapy remains the primary option, and median survival is shorter, often under a year in the metastatic setting.
Where the Cancer Spreads Matters
The location of metastases has a significant impact on prognosis. Bone-only metastases carry the best outlook, with median survival times in the range of 24 to 36 months. Visceral metastases (liver or lung involvement) are associated with shorter survival, with a median around 18 months when no bone disease is present. Brain metastases generally carry the worst prognosis across all subtypes.
The number of metastatic sites matters too. Patients with oligometastatic disease, meaning cancer has spread to only one or a few spots, sometimes do remarkably well. Retrospective studies of patients with limited metastatic disease who received aggressive local treatment (surgery and radiation in addition to systemic therapy) have documented 20-year disease-free survival in about a quarter of cases. This doesn’t apply to everyone, but it shows that a small number of metastatic sites, particularly in someone with a favorable subtype, can sometimes be controlled for years.
De Novo Versus Recurrent Stage 4
There’s a meaningful difference between being diagnosed with stage 4 breast cancer from the start (called de novo metastatic) and developing metastatic disease after previously being treated for an earlier stage. Patients diagnosed de novo tend to live longer, with a median overall survival of about 36 months compared to 27 months for those whose cancer returned after earlier treatment. The nine-month difference likely reflects the fact that recurrent cancers have already survived prior treatment and may be more resistant to therapy.
Long-Term Survival Is Real but Uncommon
About 13% of women with stage 4 breast cancer at initial diagnosis are alive ten years later. Younger women had slightly higher ten-year survival rates (around 15-16% for those under 50) compared with women aged 51 to 70 (about 12%). These long-term survivors tend to share certain characteristics: hormone receptor positive disease, limited sites of spread, strong initial response to treatment, and good overall health.
It’s worth understanding what survival statistics can and can’t tell you. The five-year survival rate of 32.6% is based on outcomes for women diagnosed years ago, some before the newest treatments were widely available. As newer targeted therapies and immunotherapies become standard, real-world survival is likely improving beyond what current statistics reflect. At the same time, population-level numbers can’t predict any individual’s outcome. Two people with the same stage and subtype can have very different trajectories based on how their specific cancer behaves and responds to treatment.
What Influences Your Individual Outlook
Several factors together shape prognosis more accurately than stage alone:
- Molecular subtype: HER2-positive and hormone receptor positive cancers generally have longer survival than triple negative.
- Number and location of metastases: Bone-only or oligometastatic disease carries a better prognosis than widespread visceral or brain involvement.
- Treatment response: How well the cancer shrinks or stabilizes with the first line of therapy is one of the strongest predictors of long-term outcome.
- Overall health: Younger patients and those without other serious health conditions tend to tolerate treatment better and live longer.
- De novo versus recurrent: Being diagnosed at stage 4 initially is associated with about nine months longer median survival than recurring after earlier-stage treatment.
Stage 4 breast cancer is not considered curable with current treatments, but it is increasingly treatable. For many patients, the goal shifts to controlling the disease as a chronic condition, cycling through different therapies as needed, sometimes for years. The gap between the shortest and longest survival times is wide, and it continues to widen as new treatments extend life for more patients.